Background {#Sec1}
==========

Short-chain enoyl-CoA hydratase(SCEH or ECHS1) deficiency, also known as crotonase deficiency, is a rare autosomal recessive hereditary disease (OMIM 616277). It was first reported by Peters et al. (2014)and caused by pathogenic variants in the ECHS1 gene \[[@CR1]\]. Clinical manifestations include mental retardation or degeneration, dystonia, seizure, hyperlacticemia, elevated lactate, and brain MRI abnormalities consistent with Leigh syndrome (LS). Theincidence of SCEH deficiency is very low, and there are only 44 cases reported abroad (Table [1](#Tab1){ref-type="table"}) and at present, no SCEH deficiency has been reported in China. In this study, the clinical data of two patients with SCEH deficiency were reported, and the relevant literatures were reviewed to improve clinicians' understanding of this disease. Table 1Clinical features of previously reported patients with ECHS1 deficiencyReferenceThis reportPeters et al.201 4\[[@CR1]\]Sakai et al.2014 \[[@CR2]\]Haack et al.2015 \[[@CR3]\]Patient IDPatient 1Patient 2Patient 1Patient 2Paient 1F1,II:2F2,II:1F3,II:6F4,II:1Genetic mutation Protein effectc.161G\>A/c.414 + 1G\>Ap.Arg54His/−c.74G\>A/c.74G\>Ap.R25H/p.R25Hc.473C \> A/c.414 + 3G \> Cp.Ala158Asp/splicingc.473C \> A/c.414 + 3G \> C;p.Ala158Asp/splicingc.2 T \> G'/c.5C \> T;p.Met1Arg/p.Ala2Valc.176A \> G/c.476A \> G;p.Asn59Ser/p.Gln159Argc.197 T \> C/c.449A \> G;p.Ile66Thr/p.Asp150Glyc.476A \> G/c.476A \> G;p.Gln159Arg/p.Gln159Argc.161G \> A/c.817A \> G;p.Arg54His/p.Lys273GluGenderFMFMMFMFMAge of onset;8 months2 yearsBirthBirth2 monthsBirthBirthBirthBirthDeathAlive at 2 yearsAlive at 5.2 years4 months8 monthsAlive at 4 years4 months11 months2.3 years7.5 yearsDevelopmentaldelay/regression++NL++NL+++Hearing loss----NLNL+++NLNLOptic atrophyND--NLNLNLNL+NLNLEpilepsy----NLNLNL++++Dystonia++NLNLNLNL+++Nystagmus+--NL++NLNLNLNLCardiomyopathyNDND--HCM--HCMHCMND--MRI: basal ganglia T2 hyperintensity+++--++++NLMRS: lactate+ND++NLNL+----Elevated plasmalactate+--++++++NLElevated pyruvate+--++NLNLNLNDNDUrinary 2-methyl, 2,3-dihydroxybutyrate++++NLND--NDNDSCPCM/SCPC/ N-acetyl-SCPCNDSCPCM+SCPCM+;SCPC+SCPCM+;SCPC+NDNDNDNDNDReferenceHaack et al.2015 \[[@CR3]\]Ferdinandusse et al.2015 \[[@CR4]\]Patient IDF5,II:3F6,II:1F7,II:2F8,II:1F9,II:2F10,II:1Patient 1Patient 2Patient3Genetic mutation Protein effectc.673 T \> C/c.673 T \> C; p.Cys225Arg/p.Cys225Argc.98 T \> C/c.176A \> G; p.Phe33Ser/p.Asn59serc.268G \> A/c.583G \> A; p.Gly90Arg/p.Gly195Serc.161G \> A/c.394G \> A;p.Arg54His/p.Ala132Thrc.161G \> A/c.431up;p.Arg54His/p.Leu145Alafs\*6c.229G \> C/c.476A \> G;p.Glu77Gln/p.Gln159Argc.817A \> G/c.817A \> G;p.Lys273Glu/p.Lys273Gluc.817 \> G/c.817A \> G;p.Lys273Glu/p.Lys273Gluc.433C \> T/c.476A \> G;p.Leu145Phe/p.Gln159ArgGenderFFFFFFFFFAge of onset;BirthBirth2 years1 YearBirth11 monthsBirthBirthEarly infancyDeathAlive at2 yearsAliveat 3 yearsAlive at 5 yearsAlive at 8 yearsAlive at 16 yearsAlive at 31 years24 h2 daysAlive at 7 yearsDevelopmentaldelay/regression++++++NLNL+Hearing lossNL+++++NLNL+Optic atrophyNLNL----++NLNL+Epilepsy++--+--+NLNLNLDystonia--++--++NLNL+NystagmusNLNLNLNL++NLNLNLCardiomyopathyHCMDCMNDNL----+--NLMRI: basal ganglia T2 hyperintensity+++NL++NL+NLMRS: lactate--NL+NL+--NLNLNLElevated plasmalactate++--++++++Elevated pyruvate+ND--NLNLNL++NDUrinary 2-methyl, 2,3-dihydroxybutyrate+ND+NDND--+++SCPCM/SCPC/ N-acetyl-SCPCNDNDNDSCPCM+SCPCM+NDNDNDSCPCM+;SPCP+ReferenceFerdinandusse et al.2015 \[[@CR4]\]Tetreault et al.2015 \[[@CR5]\]Yamada et al.2015 \[[@CR6]\]Ganetzky et al.2016 \[[@CR7]\]Patient IDPatient4P1P2P3P4III-2III-3Patient 1Patient 2Genetic mutationProtein effectc.673 T \> C/c.674G \> C;p.Cys225Arg/p.Cys225Serc.538A \> G/c.583G \> A;p.Thr180Ala/p.Gly195Serc.538A \> G/c.713C \> T;p.Thr180Ala/p.Ala238Valc.538A \> G/c.713C \> T;p.Thr180Ala/p.Ala238Valc.538A \> G/c.476A \> G;p.Thr180Ala/p.Gln159Argc.176A \> G/c.413C \> T;p.Asn59Ser/p.Ala138Valc.176A \> G/c.413C \> T;p.Asn59Ser/p.Ala138Valc.8C \> A/c.389 T \> A;p.Ala3Asp/p.Val130Aspc.8C \> A/c.389 T \> A;p.Ala3Asp/p.Val130AspGenderMFMMFFMMFAge of onset;1 year2.5 months2.9 years10 months6 months10 months7 monthsPrenatalPrenatalDeathAlive at 1 year10 monthsAlive at 18 yearsAlive at 12 yearsAlive at 12 yearsAlive at 7 years5 years16 h24 hDevelopmentaldelay/regression+++++++NLNLHearing lossNL--+++--NLNLNLOptic atrophy+--+++NLNLNLNLEpilepsyNLNLNLNL----NLNLDystonia+--+--+++NLNLNystagmusNL++++NLNLNLNLCardiomyopathyNLNLNLNLNLNDNDDCMDCMMRI: basal gangliaT2 hyperintensity+++++++NLNLMRS: lactate++------NLNLNLNLElevated plasmalactate++++------++Elevated pyruvateNDNLNLNLN/A+NL++Urinary 2-methyl, 2,3-dihydroxybutyrate+NDNDNDND--+ND+SCPCM/SCPC/N-acetyl-SCPCSCPCM+;SPCP+NDNDNDNDN-acetyl-SPCPM+N-acetyl-SPCPM+NDNDReferenceNair et al.2016 \[[@CR8]\]Olgiati et al.2016 \[[@CR9]\]Mahajan et al.2017 \[[@CR10]\]Bedoyan etal.2017 \[[@CR11]\]Huffnagel etal.2017 \[[@CR12]\]Al Mutairi et al.2017 \[[@CR13]\]Balasubramaniam et al.2017 \[[@CR14]\]Patient IDPatient 1II-1II-2Patient1Patient1Patient1Patient 1Patient 2Patient1Genetic mutationProtein effectc.842A \> G/c.842A \> G;p.Glu281Gly/p.Glu281Glyc.232G \> T/c.518C \> T;p.Glu78Ter/p.Ala173Valc.232G \> T/c.518C \> T;p.Glu78Ter/p.Ala173Valc.518C \> T/c.817A \> G;p.Ala173Val/p.Lys273Gluc.836 T \> C/c.8C \> A;p.Phe279Ser/p.Ala3Aspc.229G \> C/c.563C \> Tp.Glu77Gln/p.Ala188Valc.88 + 5G \> A/c.88 + 5G \> A;p.Ala31Glufs\*23/p.Ala31Glufs\*23c.88 + 5G \> A/c.88 + 5G \> A;p.Ala31Glufs\*23/p.Ala31Glufs\*23c.476A \> G/c.538A \> G; p.Gln159Arg/p.Thr180AlaGenderFMMMMFFMFAge of onset;Birth3.5 years4.5 years8 yearsBirth6 weeksBirthBirth17 monthsDeath24 hAlive at 17 yearsAlive at 15 yearsAlive at 8 years39 daysAlive at 26 years2 days8 hAlive at 4.5 yearsDevelopmentaldelay/regression++--NLNL+NLNL+Hearing lossNLNL--NL+--NLNL--Optic atrophyNLNL--NL--+NLNL--EpilepsyNL----NLNL--NLNLNLDystoniaNL+++++NLNL+NystagmusNLNL--NLNL+NLNLNLCardiomyopathy--NLNLNLND--NDNDNLMRI: basal ganglia T2 hyperintensityNL+++++NDND+MRS: lactateNL--NLNL+--NDNDNLElevated plasmalactate+------+++++Elevated pyruvate------ND+--+NL--Urinary 2-methyl, 2,3-dihydroxybutyrate+----ND+NDNDNDNDSCPCM/SCPC/ N-acetyl-SCPCNDSPCPM+;N-acetyl-SPCPM+SPCPM+;N-acetyl-SPCPM+NDNDSCPCM+;SCPC+; N-acetyl-SCPC+NDNDNDReferenceOgawa et al.2017 \[[@CR15]\]Fitzsimons et al.2018 \[[@CR16]\]Carlston et al.2018 \[[@CR17]\]Shayota et al.2018 \[[@CR18]\]Patient IDPt376Pt536Pt1038Pt1135Patient 1Patient 2Patient 3Patient 4Patient 1Patient1Genetic mutation Protein effectc.98 T \> C/c.176A \> G;p.Phe33Ser/p.Asn59Serc.5C \> T/c.1A \> G;p.Ala2Val/p.Met1Valc.5C \> T/c.176A \> G;p.Ala2Val/p.Asn59Serc.5C \> T/c.176A \> G;p.Ala2Val/p.Asn59Serc.476A \> G,/c.476A \> G;p.Gln159Arg/p.Gln159Argc.538A \> G/ c.538A \> G, p.Thr180Ala/p.Thr180Alac.538A \> G/ c.538A \> G, p.Thr180Ala/p.Thr180Alac.538A \> G/ .538A \> G, p.Thr180Ala/p.Thr180Alac.79 T \> G/c.789_790del;p.Phe27Val/p.Phe263fsc.538A \> G/c.444G \> Tp.T180A/p.M148IGenderNLNLNLNLMMFMMMAge of onset;NLNLNLNL5 months3 months5 months2 weeks1 year2.5 monthsDeathNLNLNLNL4 years21 months28 months13 months9 yearsAlive at 15 monthsDevelopmentaldelay/regressionNLNLNLNL++++++Hearing lossNLNLNLNLNLNLNLNL+NDOptic atrophyNLNLNLNLNLNLNLNL--NDEpilepsyNLNLNLNL++++--+DystoniaNLNLNLNL++++--+NystagmusNLNLNLNL+NLNLNLNLNLCardiomyopathyNDNDNDNDNDNDNDNDNDNDMRI: basal ganglia T2 hyperintensityNDNDNDND++++++MRS: lactateNDNDNDND++--++NLElevated plasmalactateNDNDNDND++++--+Elevated pyruvateNDNDNDNDNDNDNDND--Urinary 2-methyl, 2,3-dihydroxybutyrateNDNDNDND++++--NDSCPCM/SCPC/ N-acetyl-SCPCNDNDNDNDSPCP+NDNDSPSP+NDND*NL,* not listed;*ND,* not determined, *HCM* hypertrophic cardiomyopathy, *DCM* dilated cardiomyopathy, *SCPCM* S-(2-caboxypropyl)cysteamine, *SCPC* S-(2-carboxypropyl)cysteine, *N-acetyl-SCPC* N-acetyl-S-(2-carboxypropyl)-cysteine (N-acetyl-methacryl-l-cysteine

Case presentation {#Sec2}
=================

Case 1 {#Sec3}
------

The child was a 2 year- old girl. She was born by caesarian section for fetal transverse presentation at term with birth weight 3.25 kg (percentile 50th--75th), height 48 cm (percentile 10th--25th), and head circumference 34 cm (percentile 50th). Her birth history was unremarkable and her early milestones were appropriate. From 8 months of age onwards motor developmental delay was noted. By 1 year of age, she had obvious developmental regression due to infection, but symptoms improved slightly after the infection was treated. The patient was first evaluated in our hospital at 14 months due to severe developmental delay. She was unable to sit alone or crawl, accompanied by language dysfunction, poor fine motion, and taking simple instructions. At this time, the patient growth parameters were: weight of 10 kg (percentile 3th--10th), length of 83 cm (percentile 10th--25th), and head circumference of 46.5 cm (percentile 25th--50th). Developmentally, she had hypotonia, language development delay, mental retardation and nystagmus. Elevated levels of blood lactate 4.84 mmol/L (normal 0.7--2.1 mmol/L), pyruvic acid122μmol/L (normal 20--100 mmol/L), and TSH3UL1.081 mTU/L(normal 1.7--9.1 mTU/L)were noted. Blood ammonia, blood routine, β-hydroxybutyric acid, ceruloplasmin, blood calcium/phosphorus/alkaline phosphatase, serum vitamin D, liver and kidney function, electrolytes were all normal. Urine organic acid analysis and electroencephalogram (EEG) in 2018 was normal, brain MRI (Fig. [1](#Fig1){ref-type="fig"}a, A2) showed bilateral pale globular morphology and signal changes which suggested the possibility of genetic metabolic diseases. MRS showed bilateral lesions with inverted lactate peaks. Re-examination of urine metabolism in 2019 showed that 2,3-dihydroxy-2-methylbutyric acid was detected significantly. Fig. 1**a** Brain MRI of patient 1 showed bilateral globus pallidus swelling and abnormal signal (as shown by arrow), T1 W1 (A1) showed low signal and T2 W1 (A2) showed high signal; **b** Brain MRI of patient 2 showed a little patchy abnormal signal of bilateral globus pallidus (as shown by arrow), small patchy shadow of left globus pallidus adjacent to anterior limb of internal capsule showed slightly obvious, and both T2WI-flair(B1) and T2WI(B2)showed high signal

The genomic DNA was isolated from blood and processed for IDT The xGen Exome Research Panel on Hiseq-Illumina NGS platform. Whole exome sequencing analysis (Fig. [2](#Fig2){ref-type="fig"}) revealed that there were ECHS1 gene heterozygous mutations following: c.161G \> A in exon 2 in the chr10:135184189 region and c.414 + 1G \> A exists in intron 3 in the chr10:135183407 region, which were inherited from her mother and father respectively. The c.161G \> A (p.Arg54His) has been previously reported in compound heterozygous state in clinically affected patients (Haack et al., 2015), and which may be pathogenic. c.414 + 1G \> A genes were not reported in ClinVar, OMIM and HGMD databases, and Mutation Taster suggested the variant to be disease-causing. Fig. 2Gene detection of patients 1 and their parents in total exome gene detection. The ECHS1 gene of patient 1 had c.161G \> A and c.414 + 1G \> A compound heterozygous mutation, the ECHS1 gene of his mother had c.161G \> A heterozygous mutation, and the ECHS1 gene of his father had c.414 + 1G \> A heterozygous mutation

Case 2 {#Sec4}
------

Patient number 2 was a 5 year- old boy. He was born at 39 weeks of gestation by normal vaginal delivery after an uneventful pregnancy and the product of the second pregnancy of his mother (spontaneous abortion of the first fetus). His birth weight was 3.3 kg (percentile 25th--50th), height 49 cm (percentile 10th--25th), head circumference33.5 cm (percentile 25th--50th) with normal Apgar scores. There were no metabolic disturbances observed post-delivery. Developmental milestones were normally reached. Unsteady gait was noticed at 2 years of age with developmental regression, foot-pad walking, unable to run and jump, involuntary movement, poor fine activity, hypermyotonia and language dysfunction. His growth parameters were a weight of 11.5 kg (percentile 10th--25th), length of 85 cm (percentile 10th--25th), and head circumference of 48 cm (percentile 25th--50th). Elevated levels of α-hydroxybutyrate dehydrogenase 223 U/L (normal 2--25 U/L), lactate dehydrogenase 266 U/L (normal 106--211 U/L), creatine kinase isoenzyme 36 U/L (normal 0--25 U/L) were noted. Blood lactic acid, blood ammonia, pyruvic acid, blood routine, blood gas analysis, liver and kidney function, electrolytes were all normal. No abnormalities were found in the serum tandem mass spectrometry and urinary organic acid analysis in2017. Brian MRI (Fig. [1](#Fig1){ref-type="fig"}B1, B2) showed a few abnormal signals in the bilateral globus pallidus, and slightly obvious shadows in the left globus pallidus. Meanwhile, EEG was normal. Re-screening of urinary metabolism in 2019 suggested that 2, 3-dihydroxy-2-methylbutyric acid was slightly increased. After conducting further special metabolic examination of the urine, it was found that the concentration of S-(2-caboxypropyl) cysteamine (SCPCM) was 2.83 micromol/mmolCr, which is about four times the upper limit of reference value.

Detection of whole exome sequencing of genomic DNA showed that there was a c.74G \> A mutation in the chr10:135186764 region (exon 1) of ECHS1 gene. Family sequencing data showed that his mother carried the above-mentioned heterozygous mutation. High-throughput sequencing data indicated that there was a deletion of heterozygosity in his father. c.74G \> A was not reported in ClinVar, OMIM and HGMD, ExAC, dpSNP and other databases, and the missense mutation may be pathogenic.

Discussion and conclusion {#Sec5}
=========================

SCEH(also known as crotonase) is a 290 amino acid protein encoded by ECHS1 on chromosome 10 and localized in the mitochondrial matrix as a 160 kD ahomohexameric enzyme \[[@CR4], [@CR19]\]. SCEH has broad substrate specificity for acyl-CoAs with chain lengths up to 10 carbon atoms, although it shows greatest activity towards crotonyl-CoA. In the metabolic pathway, the functions of SCEH is to hydrate the double bond between the second and third carbon of enoyl-CoAs. In addition, its function in the oxidation of short chain acyl-CoAs, SCEH also has activity on the degradation intermediates of branched-chain acyl-CoAs, particularly valine, isoleucine and leucine. However, recent functional studies have shown that SCEH is a crucial enzyme in valine metabolism, but not isoleucine metabolism, and has limited effect on mitochondrial fatty acid oxidation \[[@CR11], [@CR13]\].

Pathogenic variants of biallelic allele in ECHS1 leads to the decrease of SCEH activity,and results in clinical manifestations of Leigh syndrome with early onset of hypotension, growth retardation or degeneration, cardiomyopathy, dystonia, sensorineural hearing loss, hypotension and malnutrition. Blood and cerebrospinal fluid (CSF) lactate and pyruvate levels are usually elevated. Brain MRI may show white matter changes or Leigh syndrome-like pattern affecting brainstem and basal ganglia, similar to other genetic energy metabolic disorders \[[@CR3], [@CR11], [@CR18]\]. Both two patients we reported in this study had developmental retardation, dystonia, feeding difficulties and malnutrition. Patient 1 also had nystagmus, elevated blood lactate and pyruvate. Serum alpha-hydroxybutyrate dehydrogenase and lactate dehydrogenase and creatine kinase isoenzymes in patient 2 were elevated. Both two patients had abnormal signals of bilateral globus pallidus on brian MRI. Patient 1 showed inverted lactate peaks in bilateral lesions on brian MRS, which was consistent with the results reported in the literatures.

The pathophysiology of this disease is still unclear. It has been hypothesized to be secondary to toxic accumulation of intermediate metabolites that exert brain toxicity and derange mitochondrial energy production. Previous studies have shown that ECHS1 mutation can induce accumulation of active metabolites of methacrylyl-CoA and acryloyl-CoA \[[@CR7], [@CR13]\]. SCEH protein has high specificity and activity to methacrylyl-CoA, which is a toxic compound that tends to form adducts with cysteine and causes cell damage. Therefore, the loss of SCEH enzyme activity may lead to the accumulation of this toxic compound and pathogenicity \[[@CR9]\].

Evidence is emerging to support that,levels may correlate with disease severity. In retrospective analysis of mitochondrial encephalopathy and transient 3-methylglutaconic aciduria caused by ECHS1 deficiency, Huffnagel et al. suggested that S-(2-carboxypropyl) cysteine, S-(2-carboxypropyl) cysteine and N-acetyl-S-(2-carboxypropyl) cysteine might been useful diagnostic makers of SCEH deficiency \[[@CR12]\]. For patients with mild forms of deficiency, only N-acetyl-S-(2-carboxypropyl) cysteine level is increased in the urine, suggesting that the metabolites of methacrylyl-CoA are important diagnostic markers of the mild and severe forms of ECHS1 deficiency. N-acetyl-S-(2-carboxypropyl)cysteine and its derivatives are formed from methacrylyl-CoA, so methacrylyl-CoA is also an important diagnostic marker for mild SCEHdeficiency \[[@CR6], [@CR12], [@CR20], [@CR21]\]. Peter et al. found that the content of 2,3-dihydroxy-2-methylbutyrate in urine of two SCEHdeficiency patients increased in the study of ECHS1mutations in LS suggesting that the metabolite may be a common biochemical change in SCEHdeficiency \[[@CR1]\].

Fitzsimons et al. studied the role of SCEH in the metabolism of fatty acids and branched chain amino acids in four patients with ECHS1 gene mutation. The results of enzyme activity measurement and western blot analysis strongly indicated that there was a correlation between residual SCEH activity and severity of clinical symptoms \[[@CR12], [@CR16]\]. In this study, two patients received urine organic analysis, but no abnormality was found. The second urine metabolic test used urease method, and found 2, 3-dihydroxy-2-methylbutyric acid increased, which was related to the sensitivity of the detection method. 2,3-dihydroxy-2-methylbutyric acid in urine was only slightly elevated in patient 2 due to treatment. After further special urine examination was performed, S-(2-carboxypropyl) cysteamine was found increased significantly, which supported the diagnosis of SCEH deficiency and was consistent with gene diagnosis. The organic acid extraction technique in urine metabolism examination has low sensitivity in such patients and urease method can be used to improve the positive rate.

Three rare variants were detected by clinical exome sequencing of the probands.. Patient 1 had a compound heterozygous mutation of pathogenic variant c.414 + 1G \> A and likely pathogenic variant c.161G \> A, which was inherited from her father and mother respectively. Patient 2 has a homozygous mutation of c.74G \> A. His mother carried a heterozygous mutation and his father had a gene deletion. c.161G \> A ECHS1 variant has been previously reported by Haack et al. for the first time in the study of mitochondrial encephalopathy with cardiac involvement caused by ECHS1 deficiency. In his study, three patients in 10 families were found to carry c.161G \> A mutation gene. All these three patients and patient 1 in our study had onset in infancy, accompanied by developmental retardation. Some patients had the same manifestations as patient 1, such as dystonia, nystagmus. Elevated serum lactate level, bilateral basal ganglia signal changes on brian MRI, and lactate peak on MRS were observed. Two of the three reported cases showed elevated urine S-(2-caboxypropyl)cysteamine concentration by urine specific metabolic screening. The c.161G \> A variant has a population frequency of 0.000032 in East Asian. The pathogenic c.74G \> A mutation is novel and never been reported before.

SCEH deficiency is a high mortality rate and poor prognosis disease. Most patients died of severe metabolic acidosis in infancy. So far, no standard therapy for ECHS1 deficiency exists for the treatment of SCEH deficiency. Some patients have received "cocktail therapy", and the production of the toxic methacrylyl-CoA and its derivatives might be avoided with specific dietary regimens that reduce the workload on the valine catabolic pathway \[[@CR9]\]. Some researchers have observed the increase of N-acetyl-S-(2-carboxypropyl) cysteine levels in patients with SCEH and HIBCH, suggesting that glutathione metabolism may be the cause of sulfhydryl-containing metabolites in urine. The combination of glutathione and glutathione S-transferase is an effective detoxification method for excretion of this abnormal metabolite through urine. Therefore, it is believed that supplementation of N-acetylcysteine may be beneficial to increase the content of glutathione, thereby eliminating toxic metabolites \[[@CR18]\]. Some experts suggest that the combined approach of N-acetylcysteine supplementation and a restricted diet can be safely utilized in SCEH deficiency patients. In addition, there are literatures on ketogenic diet for SCEH deficiency \[[@CR11], [@CR16], [@CR17]\], but the efficacy and safety of it remains yet to be studied. In this study, two patients were treated with cocktail therapy, low valine diet and rehabilitation therapy. Both of their motor functions were slightly improved after treatment.

In conclusion, SCEH deficiency caused by mutations of ECHS1 gene is a rare mitochondrial disease and patients typically present with psychomotor retardation, dystonia, nystagmus, cardiomyopathy, sensorineural hearing impairment, hyperlacticemia and Leigh syndrome-like cranial MRI in infants and young children. Elevated levels of 2,3-dihydroxy-2-methylbutyrate, S-(2-carboxypropyl) cysteine, S-(2-carboxypropyl) cysteine and N-acetyl-S-(2-carboxypropyl) cysteine can be diagnostic clues towards the disease spectrum of ECHS1 mutations in patients with an early-onset and mitochondrial encephalopathy. Early cocktail therapy, valine restriction diet and N-acetylcysteine supplementation can improve the prognosis of patients.
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**Additional file 1:** CARE checklist.

DCM

:   Dilated cardiomyopathy

HCM

:   Hypertrophic cardiomyopathy

N-acetyl-SCPC

:   N-acetyl-S-(2-carboxypropyl)-cysteine (N-acetyl-methacryl-l-cysteine

ND

:   Not determined

NL

:   Not listed

SCPC

:   S-(2-carboxypropyl)cysteine

SCPCM

:   S-(2-caboxypropyl)cysteamine
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